Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Ocugen Bulls Are Overlooking Its FDA Approval Hurdles

The FDA seems highly unlikely to approve the Covaxin vaccine, making OCGN stock an excellent name to short going forward.

IronNet Is a Mediocre Firm in a Strong Sector

IRNT stock is too difficult to pin down and it looks like there are better cybersecurity opportunities in the market.

There’s No Reason to Buy Cloudflare as Market Does an About-Face

Avoid NET stock because although the company is clearly strong, the market also clearly gave it excessive reward that made it too expensive. 

A Turnaround Is Unlikely For BlackBerry As Internals Weaken Further

Another deplorable quarter suggests that BB stock is failing to grow its top line and will continue to disappoint its investors.

Canoo Could Run Short of Cash Before EV Production Begins, So Expect a Dip

If Canoo hits a cash crunch before it starts making EVs, GOEV stock could fall from fear given its cash burn plans.

WHO Approval Won’t Move Ocugen Stock Very Much Over the Long Term

The WHO's nod of approval wont be fruitful to OCGN stock in blowing past the regulatory hurdles in the North American Covid 19 vaccine market

Wait for Weakness Before Buying Carnival Stock

With Carnival's "recovery" fully priced into CCL stock, it isn't sailing back to $50 per share. So steer clear of it for now.

Toyota Stock Is Going to Get Weaker as It Bucks the Full EV Trend

Toyota today is the most valuable car company in the world, and the stock sports a nice dividend. But its resistance to the electric revolution is dimming its future prospects

Lucid Motors Stock Has Gotten Too Far Ahead of Itself to Be Worth Holding Here

With LCID stock trading at nose4bleed levels and facing intense competition, the shares are unlikely to climb much.

Pandemic-darling Peloton Stock Is Too Unpredictable and Expensive

With Peloton facing many tough hurdles and PTON stock still trading at a very high valuation, the shares are not appealing at this point.

Avoid Zoom as It Grapples With Reopening, Tough Competitors

With Zoom facing tough competition and the pandemic greatly easing, ZM stock remains too expensive at this point.

The Story’s Not Changing Anytime Soon for Clover Stock

As fixing its profitability problem remains a work-in-progress, and as a market downturn will likely send it plummeting once more, avoiding CLOV stock is still your best move.

ContextLogic Works On Borrowed Time as It Can’t Seem To Turn a Profit

If you’re expecting the next e-commerce giant, WISH stock isn't it. ContextLogic can't turn a profit and the shares have languished since the December IPO.

AMC Stock Is Due for a Tumble Back to Reality as the Pandemic Ends

Among the obstacles facing AMC stock are the power of the streaming services and the erosion of the meme-stock investors.

Camber Energy Is a Dwindling Light in a Dark Room

Highly speculative Camber Energy stock is likely to fall without further info. CEI stock has a new accountant, no recent financials, no indication when its Viking Energy merger will close and no ROI analysis on the ESG deal.

Globalstar Is Coming Off a Speculative Peak With No Profits In Sight

Globalstar stock is coming off a speculative peak with no profits in sight. GSAT stock could tread water for a while until investors can see that its subscriber base and revenue are growing again.

The Recent Pullback in AMC Entertainment Stock Is Just the Start

Once its meme bubble bursts, AMC stock will fall toward its underlying value (likely a price in the single-digits). With this in mind, avoid it at all costs.

7 Chinese Stocks to Sell Before the Next ‘Lehman Brothers’ Event

With the China Evergrande crisis imposing a dark cloud on the nation’s commercial paper, it’s time to trim Chinese stocks.

Ocugen Still Lacks a Path to U.S. Profits

Ocugen still lacks a proper catalyst and nothing has changed for it. As a result, investors should avoid OCGN stock.